CD279 Antibody: Enhance Your Research with Quality Solutions

cd279, also known as PD-1 (Programmed Cell Death Protein 1), plays a crucial role in immune regulation and is a key target for immunotherapy in cancer treatment. Alpha Lifetech Incorporation offers a high-quality CD279 antibody designed to aid in the research and development of therapies targeting this immune checkpoint. This antibody demonstrates exceptional specificity and sensitivity, ensuring reliable results for various applications, including flow cytometry, immunohistochemistry, and western blotting, Researchers can utilize this antibody to explore the PD-1 pathway's impact on T cell activation and immune response modulation. With its robust performance and easy-to-use format, Alpha Lifetech's CD279 antibody supports breakthroughs in understanding tumoral immune evasion and improving cancer therapies. Choose this innovative antibody to advance your research and contribute to the transformative field of immuno-oncology. Whether you are working in basic research or therapeutic development, this product is an essential tool for any laboratory focused on immune checkpoint studies

Hot Selling Product

ADT1443-Nivolumab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1663-Toripalimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

ADT1274-Geptanolimab Biosimilar-(PDCD1/PD-1/CD279)-Research Biosimilar Antibody

ADT1322-Iparomlimab Biosimilar-(PDCD1/PD-1/CD279)-Research Biosimilar Antibody

ADT1233-Ezabenlimab Biosimilar-(PDCD1/PD-1/CD279)-Research Biosimilar Antibody

ALP64619-Recombinant Human CD279/PD-1 Protein, His Tag

Practical Strategies for cd279 antibody Your Trusted OEM Partner Application

At Alpha Lifetech Inc., we understand the growing demand for high-quality research reagents in the life sciences sector. As an established OEM partner, we specialize in the production and development of innovative biotechnological products, including our renowned cd279 antibody. Our team, comprised of experienced scientists with a strong background in membrane protein production, nanobody discovery, and monoclonal antibody development, ensures that we meet the specific needs of our global partners. To support your research needs, we offer practical strategies for utilizing cd279 antibodies effectively. Firstly, our extensive catalog features nearly 10,000 spot membrane protein reagents, providing you with the diverse options necessary to optimize experimental outcomes. Secondly, we prioritize quality and consistency in our manufacturing processes, ensuring that each product is thoroughly validated for reproducibility. By collaborating with Alpha Lifetech, you gain a reliable partner committed to enhancing your research capabilities with cutting-edge materials. Investing in our cd279 antibody not only streamlines your research projects but also fosters innovation in your field. As your trusted OEM partner, we invite global buyers to explore our offerings and leverage our expertise to accelerate discovery. Together, we can advance science and improve outcomes in life sciences research.

Practical Strategies for cd279 Antibody Your Trusted OEM Partner Application

Application	Target Cell Types	Recommended Concentration	Staining Method	Notes
Flow Cytometry	T cells, B cells	1-2 µg/106 cells	Direct staining with fluorochrome-conjugated antibodies	Use appropriate isotype controls
Immunohistochemistry	Tissue sections	2-5 µg/ml	Blocking followed by primary and secondary antibody incubation	Optimize fixation protocol for best results
Western Blot	Cell lysates	0.5-1 µg/ml	Transfer to membrane followed by incubation	Ensure proper transfer efficiency
ELISA	Serum or plasma samples	0.1-0.5 µg/ml	Capture and detection antibodies	Include standards for quantitative analysis

Antibody Production Yield Over Time

The selected data chart highlights the production yield of antibodies over a one-year period, from January to December. Each point on the line represents the yield in milligrams (mg) achieved each month. Notably, the data illustrates a steady increase in yield during the second half of the year, suggesting potential improvements in processes or techniques deployed during this time. Early months show some fluctuation, reflecting typical challenges faced in scaling production, which could include optimizing cultivation conditions or addressing batch variances. Through tracking this data, organizations can identify trends and implement strategies for continual improvement in antibody production, which is essential for research and therapeutic applications. The gradual rise in yield towards year's end indicates successful adaptation and optimization of production methods, underlining the importance of ongoing assessment and refinement in the antibody development process.